<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346407</url>
  </required_header>
  <id_info>
    <org_study_id>20.N0042</org_study_id>
    <nct_id>NCT04346407</nct_id>
  </id_info>
  <brief_title>Dronabinol for Post-operative Pain After Lumbar Fusion</brief_title>
  <official_title>Impact of Dronabinol on Post-operative Pain After Lumbar Fusion for Degenerative Disorders of the Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey L Gum MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norton Leatherman Spine Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impact of 2.5mg of oral Dronabinol daily versus placebo on post-operative opioid consumption&#xD;
      on patients aged 18 to 65 years old undergoing 1 to 3 level posterolateral fusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind clinical trial comparing 2.5mg of oral Dronabinol daily&#xD;
      starting with pre-op cocktail and continued twice daily for three days after surgery versus&#xD;
      placebo for patients aged 18 to 65 years old undergoing 1 to 3 level posterolateral fusion.&#xD;
      The outcome of interest is post-operative opioid consumption defined as cumulative Morphine&#xD;
      Milligram Equivalents at 72 hours after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind Placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo, randomization and blinding will be maintained by the Hospital Pharmacy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Morphine Milligrams at 72 hours post-operative</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Cumulative Morphine Milligrams consumed in-hospital 72 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Morphine Milligrams at 24 hours post-operative</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Cumulative Morphine Milligrams consumed in-hospital 24 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Morphine Milligrams at 48 hours post-operative</measure>
    <time_frame>48 hours post-operative</time_frame>
    <description>Cumulative Morphine Milligrams consumed in-hospital 48 hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst pain in past 24 hours post-operative</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Worst pain in past 24 hours post-op on a scale of 0 to 10, with 0 as no pain and 10 as worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst pain in past 48 hours post-operative</measure>
    <time_frame>48 hours post-operative</time_frame>
    <description>Worst pain in past 48 hours post-op on a scale of 0 to 10, with 0 as no pain and 10 as worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst pain in past 72 hours post-operative</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Worst pain in past 72 hours post-op on a scale of 0 to 10, with 0 as no pain and 10 as worst pain imaginable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol 2.5mg Cap</intervention_name>
    <description>2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery</description>
    <arm_group_label>Dronabinol</arm_group_label>
    <other_name>Marinol</other_name>
    <other_name>Syndros</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 65 years old&#xD;
&#xD;
          -  Patients undergoing 1 to 3 level posterolateral fusion&#xD;
&#xD;
          -  Opioid na√Øve or not&#xD;
&#xD;
          -  No prior spine fusion&#xD;
&#xD;
          -  Willing and able to sign an Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for surgery is fracture, tumor or infection&#xD;
&#xD;
          -  Comorbid psychiatric diagnosis requiring therapy and/or medication&#xD;
&#xD;
          -  Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia)&#xD;
&#xD;
          -  Has hepatic disease&#xD;
&#xD;
          -  On workers compensation/disability/litigation&#xD;
&#xD;
          -  Known adverse reaction to medications to be administered&#xD;
&#xD;
          -  History of alcohol and drug abuse&#xD;
&#xD;
          -  On long-acting narcotic pain medication (including extended release narcotic pain&#xD;
             medications and methadone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Gum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norton Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Norton Leatherman Spine Center</investigator_affiliation>
    <investigator_full_name>Jeffrey L Gum MD</investigator_full_name>
    <investigator_title>Attending Spine Surgeon</investigator_title>
  </responsible_party>
  <keyword>Lumbar Fusion</keyword>
  <keyword>Post-operative Opioid Consumption</keyword>
  <keyword>Post-operative Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

